Recent advances in neuroblastoma (NB) research addressed that epigenetic alterations such as hypermethylation of promoter sequences, with consequent silencing of tumor-suppressor genes, can have significant roles in the tumorigenesis of NB. However, the exact role of epigenetic alterations, except for DNA hypermethylation, remains to be elucidated in NB research. In this paper, we clarified the direct binding of MYCN to Bmi1 promoter and upregulation of Bmi1 transcription by MYCN. Mutation introduction into an MYCN binding site in the Bmi1 promoter suggests that MYCN has more important roles in the transcription of Bmi1 than E2F-related Bmi1 regulation. A correlation between MYCN and polycomb protein Bmi1 expression was observed in primary NB tumors. Expression of Bmi1 resulted in the acceleration of proliferation and colony formation in NB cells. Bmi1-related inhibition of NB cell differentiation was confirmed by neurite extension assay and analysis of differentiation marker molecules. Intriguingly, the above-mentioned Bmi1-related regulation of the NB cell phenotype seems not to be mediated only by p14ARF/p16INK4a in NB cells. Expression profiling analysis using a tumor-specific cDNA microarray addressed the Bmi1-dependent repression of KIF1Bb and TSLC1, which have important roles in predicting the prognosis of NB. Chromatin immunoprecipitation assay showed that KIF1Bb and TSLC1 are direct targets of Bmi1 in NB cells. These findings suggest that MYCN induces Bmi1 expression, resulting in the repression of tumor suppressors through Polycomb group genemediated epigenetic chromosome modification. NB cell proliferation and differentiation seem to be partially dependent on the MYCN/Bmi1/tumor-suppressor pathways.
Introduction
In tumorigenesis, besides the well-known genetic changes that occur in cancer, such as the deletion of tumor-suppressor genes (TSGs), amplification/activation of oncogenes and loss of heterozygosity or gene mutations in tumor-associated genes (Hanahan and Weinberg, 2000) , epigenetic alterations, such as altered DNA methylation, misregulation of chromatin remodeling by histone modifications and aberrant expression of Polycomb group genes (PcGs) proteins have emerged as common hallmarks of many cancers (Jones and Baylin, 2002; Sparmann and van Lohuizen, 2006; Esteller, 2007; Rajasekhar and Begemann, 2007) . PcGs are usually considered to be transcriptional repressors that are required for maintaining the correct spatial and temporal expressions of homeotic genes during development. (Schwartz and Pirrotta, 2008) . Recent biochemical approaches have established that PcG proteins form multiprotein complexes, known as PolycombRepressive Complexes (PRCs). PRC2 contain Ezh2, EED, Suz12 and RbAp48, whereas the PRC1 complex consists of 410 subunits, including the oncoprotein Bmi1 and the HPC proteins, namely HPH1-3, RING1-2 and SCML (Rajasekhar and Begemann, 2007) . In addition to being essential regulators of embryonic development, PcGs have also emerged as key players in the maintenance of adult stem cell populations (Valk-Lingbeek et al., 2004; Pietersen and van Lohuizen, 2008) . For example, Bmi1 is required for the selfrenewal of hematopoietic and neural stem cells (Lessard and Sauvageau, 2003; Molofsky et al., 2003 , Iwama et al., 2004 , whereas the overexpression of EZH2 prevents hematopoietic stem cell exhaustion (Kamminga et al., 2005) . Consistent with their critical roles in development, differentiation and stem cell renewal, several PcGs are oncogenes, overexpressed in both solid and hematopoietic cancers (Valk-Lingbeek et al., 2004; Rajasekhar and Begemann, 2007) . Neuroblastoma (NB) is one of the most common malignant solid tumors occurring in infancy and childhood and accounts for 10% of all pediatric cancers (Westemann and Schwab, 2002) . NBs are derived from sympathetic neuroblasts with various clinical outcomes from spontaneous regression, caused by neuronal differentiation and/or apoptotic cell death, to malignant progression. Extensive cytogenetic and molecular genetic studies identified that genetic abnormalities, such as loss of the short arm of chromosome 1 (1p), amplification of MYCN and 17q gain, are frequently observed and often associated with poor clinical outcome (Brodeur et al., 1984; Caron, 1995) . Although numerous genetic abnormalities, including MYCN amplification, are involved in the development and/or progression of NB, the molecular mechanisms responsible for the pathogenesis of aggressive NB remain unclear. Epigenetic alterations, such as hypermethylation of promoter sequences, with consequent silencing of TSGs, such as CASP8, RASSF1A, CD44, TSP-1 and PTGER2, can have significant roles in the tumorigenesis of NB (Teitz et al., 2000; Yan et al., 2003; Yang et al., 2003 Yang et al., , 2004 Sugino et al., 2007) . However, it was reported that the expression of several tumor-suppressor candidate genes, such as KIF1Bb and TSLC1, is suppressed in NB cells, but the percentage of pathological mutations and promoter methylation in NB tumors was not so high Munirajan et al., 2008) . For the promoter DNA methylation-independent gene repression, the PcG complex might have a role in NB cell proliferation and differentiation, although the exact role of PcG in NB tumorigenesis remains to be elucidated. Regarding Bmi1 regulation in NB, the binding of E2F-1 to Bmi1 promoter and its activation were reported, and a strong expression of Bmi1 was observed in primary NBs (Nowak et al., 2006) . However, Bmi1 expression was not evaluated according to patient prognosis, and there was no correlation between MYCN amplification and Bmi1 expression in the report. Another group reported that Bmi1 suppression by knockdown induced several differentiation marker proteins, and impaired colony formation and tumor formation in immunodeficient mice, although Bmi1 overexpression in NB cells could not function as an oncogene (Cui et al., 2006 (Cui et al., , 2007 .
In this paper, we found that MYCN directly bound to Bmi1 promoter and induced its transcription. A correlation between MYCN and Bmi1 expressions was observed in both NB cell lines and primary tumors. The expression of Bmi1 in NB cells resulted in the upregulation of proliferation and colony formation; expression profiling using a tumor-specific cDNA microarray (Ohira et al., 2005) addressed the Bmi1-dependent repression of TSGs, which has an important role in predicting the prognosis of NB.
Results
Bmi1 expression correlates with MYCN expression in NB cell lines and tumor samples First, we studied Bmi1 expression by western blotting and found that the PRC1 complex protein Bmi1 and Ring1b expressions correlated with MYCN protein expression in NB cell lines, except for SK-N-AS cells (Figure 1Aa) . At the mRNA level, we observed Bmi1 upregulation in MYCN-amplified SK-N-DZ to IMR32 cells (Figure 1Ab) . Furthermore, the Bmi1 expression in primary NB specimens was clearly detected in the nucleus of MYCN-amplified NBs compared with those of MYCN single-copy NBs (Supplementary Figure S1) , which was confirmed by statistical analysis ( Figure 1B ).
Bmi1 transcription is induced by MYCN
The above findings prompted us to study whether Bmi1 transcription is induced by MYCN in NB cells. We used Tet21/N cells expressing MYCN under the control of tetracycline (Lutz et al., 1996) . Four hours after tetracycline withdrawal, Bmi1 and Ring1b expressions were considerably increased along with MYCN induction both at mRNA and protein levels (Figure 2A a, 
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H Ochiai et al sites in the human Bmi1 promoter (ENSG00000168283) ( Figure 2B ). To study the transcriptional regulation of Bmi1 expression in NB cells, initial transfection experiments were conducted with the Bmi1 luciferase/promoter reporter construct (À1070/ þ 53), which contains the putative E-box element and E2F binding sites ( Figure 2Ca) ; the À1070/ þ 53 fragment showed significant promoter activity in an MYCN-amplified NB cell line SK-N-DZ. Deletion of À1070/À197 and À121/ þ 53 still showed considerable activity ( Figure 2Ca , activity of À196/ þ 53 fragment compared with À196/ À122), suggesting an important role of MYCN in Bmi1 promoter activity. Furthermore, this finding was confirmed by mutation of the E-box in the À196/À122 fragment (activity of À196/À122/mut). Next, we studied the effect of MYCN on Bmi1 promoter activity using the MYCN-inducing NB cell line Tet21/N. MYCN induction significantly increased promoter activity in Tet21/N cells (Figure 2Cb ). Intriguingly, we observed promoter activity even in MYCN (À) cells. We speculated that residual MYC (c-MYC) may contribute to activity in these cells (Supplementary Figure S2) MYCN binds to the E-box region in Bmi1 promoter To address whether MYCN could be recruited onto the E-box in Bmi1 promoter in NB cells, we performed chromatin immunoprecipitation (ChIP) assays by quantitative real-time PCR (qPCR). We found that MYCN binding to the Bmi1 promoter region was clearly detected in MYCN-amplified SK-N-DZ and NB-19 cells but not in MYCN-single SH-SY5Y cells (Figure 3a) . Furthermore, this observation was confirmed in MYCN-inducible Tet21/N cells (Figure 3b ), indicating that MYCN binds to the Bmi1 promoter region and has a considerable role in Bmi1 transcription in MYCNamplified NB tumors. Bmi1 regulates NB cell proliferation Next, we examined the effect of Bmi1 on the cell growth of NB cells by exogenous expression of Bmi1. SH-SY5Y cells were infected with the mock virus and the FLAGtagged Bmi1 expression virus. Cell growth was studied by the WST (water-soluble tetrazolium salt) assay and showed that Bmi1 significantly accelerated cell proliferation compared with mock cells (Figure 4a ). In the soft agar assay, Bmi1-expressing SH-SY5Y cells formed anchorage-independent colonies effectively, although colony formation was hardly detectable in parental and mock cells (Figure 4b ). Interestingly, Ring1b was increased in Bmi1-expressing SH-SY5Y cells ( Figure 4c ) and Tet21/N cells ( Figure 4e) ; the well-known Bmi1 targets p14ARF and p16INK4a protein amounts were not markedly changed by Bmi1 expression, although mRNA expression was slightly suppressed in SH-SY5Y cells. These results suggest that increased PRC1-mediated gene repression, except for p14ARF and p16INK4a, might have an important role in NB cells. In addition, we found an additive effect of MYCN induction in Bmi1-expressing Tet21/N cells, suggesting the significance of MYCN targets, except for Bmi1, in NB cell proliferation. Bmi1 knockdown by lentivirusmediated shRNA transduction strongly inhibited cell Figure S3 and data not shown), consistent with previous reports (Cui et al., 2006) .
Bmi1 controls NB cell differentiation
Treatment with TPA (12-O-tetradecanoylphorbol 13-acetate) or ATRA (all-trans-retinoic acid) effectively 
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H Ochiai et al induced NB cell differentiation, for example, neurite extension (Figure 5Aa ), and the expression of differentiation markers (Figure 5Ab and c). Interestingly, Bmi1 was downregulated at the protein level along with NB cell differentiation by TPA or ATRA treatment. To address the role of Bmi1 in NB cell differentiation, we knocked down Bmi1 using shRNA-expressing lentivirus. Intriguingly, only Bmi1 knockdown induced significant neurite extension (Figure 5Ba ) and the expression of differentiation markers GAP43 and NF68 (Figure 5Bc ), suggesting the existence of Bmi1-related regulation of NB cell differentiation.
Bmi1 binds to the promoter region of TSGs TSLC1 and KIF1Bb and suppresses transcription in NB cells To understand how Bmi1 controls NB cell proliferation and tumorigenesis, we chose to identify their target genes, except for p14ARF/p16INK4a, as we could not observe significant changes in these well-known tumor suppressors (Figures 4 and 5) . To identify the Bmi1 target genes, except for p14ARF and p16INK4a, we studied expression gene profiling using an appropriate NB cDNA microarray (named the CCC-NHR13000 chip) carrying 13 440 cDNA spots. The top 10 genes decreased by Bmi1 expression in SK-N-BE cells are listed in Table 1 . Surprisingly, the well-known tumor suppressors (TSGs) in NB TSLC1 (NM_014333.3) and KIF1Bb (AB017133) are ranked as the first and second targets, respectively. The previously reported Bmi1 target HOXA4 expression (Cao et al., 2005) was also considerably repressed by Bmi1. Consistent with our results (Figures 4 and 5) , the ranking of p14ARF/ p16INK4a was 5258. We determined the Bmi1-mediated regulation of TSLC1 and KIF1Bb transcription by semiquantitative real-time (RT)-PCR experiments using Bmi1-expressing and knocked-down NB cells and found that Bmi1 expression considerably repressed TSLC1 and KIF1Bb transcription in NB cells ( Figure 6a ). Next, we studied Bmi1 binding to the promoter regions of TSLC1 and KIF1Bb and found that Bmi1 specifically bound to the KIF1Bb (ENSG00000054523) and TSLC1 (ENSG00000105767) promoter region in NB cells. qPCR ChIP expressions confirmed Bmi1 binding to these promoters, suggesting the existence of MYCN/Bmi1-mediated TSLC1 and KIF1Bb suppression in NB. Furthermore, this Bmi1-mediated regulation of TSLC1 and KIF1Bb expression was not only in NB cells but also in squamous lung cancer QG56 cells (Supplementary Figure S4) .
Discussion
Bmi1 regulates the expression of TSGs in NB Among the PcG target genes in cancer cells, PcGmediated repression of TSGs has an indispensable role in tumorigenesis (Sparmann and van Lohuizen, 2006; Rajasekhar and Begemann, 2007) . As a result of PcG overexpression, the increased PRC1/PRC2 complexes bind to PcG target gene promoter lesions. Next, putative 
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PRC/DNA methyltransferase cross talk seems to induce aberrant DNA methylation as PRC2 member EZH2 was shown to recruit DNA methyltransferase to select target genes (Vire´et al., 2006) . In fact, PcG protein target genes have been found to display a greater likelihood of acquiring specific promoter DNA hypermethylation during cancer progression than nontarget genes (Iwama et al., 2004; Kamminga and de Haan, 2006) . It is interesting that the p16INK4a-p14ARF locus represents one of the above-identified candidates with PRCs binding and hyper DNA methylation in the promoters in cancer cells. This locus encodes two alternatively spliced gene products, the tumor-suppressor protein p16INK4a (an inhibitor of cell-cycle progression) and p14ARF (a regulator of p53) (Sherr, 2004) . Bmi1 is a well-known repressor of p16INK4a and, in some cases, such as in mammalian cells, p14ARF genes (Jacobs et al., 1999; Molofsky et al., 2006) . However, several previous reports have indicated that there could be another important Bmi1 target gene, especially in the nervous system, in addition to p16INK4a/p14ARF (Jacobs et al., 1999; Bruggeman et al., 2007) . In our study, Bmi1 overexpression accelerated the proliferation of several NB cell lines, although p14ARF/ p16INK4a repression was not so obvious (Figure 4) . Furthermore, it was previously reported that the probability of p16INK4a inactivation in NB was not high (Easton et al., 1998) . These results prompted us to screen Bmi1-dependent gene repression using a tumorspecific cDNA microarray, and we identified the repression of TSGs, KIF1Bb and TSLC1 (Table 1) . This repression was confirmed by semi-quantitative RT-PCR experiments, and the in vivo binding of Bmi1 to these promoters was addressed by ChIP assay with qPCR using Bmi1-overexpressing NB cells (Figure 6 ). Accumulating lines of evidence strongly suggest that downregulation of TSLC1 in various cancers, including lung cancer, hepatocellular carcinoma, gastric cancer, pancreatic adenocarcinoma, prostate cancer, breast cancer, nasopharyngeal carcinoma and cervical cancer, might be due to the hypermethylation of its promoter region (Murakami, 2005) . In sharp contrast to these cancers, we did not detect hypermethylation of the promoter region of the TSLC1 gene in primary NBs or NB-derived cell lines, and TSLC1 expression levels significantly correlated with the stage, Shimada's pathological classification and MYCN amplification status . We also found that KIF1Bb, located at chromosome 1p36.2, was significantly suppressed in MYCN-amplified NB samples, although its mutation rate was not high and promoter hypermethylation was not observed (Munirajan et al., 2008) . Furthermore, a previous report mentioned that a cluster of genes located in 1p36, including KIF1Bb, is downregulated in NBs with poor prognosis, but was not due to CpG island methylation (Care´n et al., 2005) . Taken together, it suggests that MYCN-induced Bmi1 suppresses several TSGs by their promoter silencing and contributes to NB tumorigenesis. Systematic analysis of PcG binding to gene promoter lesions will be required for the study of epigenetic regulation of tumorigenesis-related gene expression in NB.
Regulation of Bmi1 gene transcription
Despite these important functions in development and tumorigenesis, little is known about transcriptional regulation of the Bmi1 gene. The transcription factors known to regulate Bmi1 expression are sonic hedgehogactivated Gli1 protein (Leung et al., 2004) , E2F family members (Nowak et al., 2006) , zinc-finger transcription factor SALL4 (Yang J et al., 2007) and c-Myc (Guney et al., 2006) . As E2F1 regulates NB tumorigenesis through direct binding to MYCN promoter and its activation, E2F may regulate NB cells using complicated MYCN, MYCN/Bmi1 and Bmi1 regulation mechanisms (Strieder and Lutz, 2003; Kramps et al., 2004) . Abbreviation: NB, neuroblastoma. Bmi1 was overexpressed by lentivirus-mediated transduction in SK-N-BE cells. Total RNA was extracted and subjected to expression profiling analysis by an appropriate NB cDNA microarray as described in the 'Materials and methods' section. The results are the averages of at least three experiments and the top 10 genes suppressed are presented. Overall, 11 293 genes were analyzed. We will inform the microarray data if there is a request.
In this paper, we found that MYCN directly binds to the Bmi1 promoter in vivo and that binding is enhanced by MYCN amplification in NB cell lines and MYCN induction using tetracycline-withdrawal-based gene induction plasmid (Figure 3) . MYCN expression correlates with Bmi1 levels both at mRNA and protein levels in NB cell lines ( Figures 1A, 2a) and NB tumor samples ( Figure 1b) . Next, we studied the role of the MYCN binding site and several E2F binding sites in Bmi1 transcriptional regulation using a luciferase expression system (Figure 2) . Intriguingly, we found that significantly high luciferase activities of E-box þ E2F site promoter (Figure 2c , À196/ þ 53 fragment) and E2F site deletion from this fragment (Figure 2c , À196/À122 fragment) resulted in only a modest reduction of activity. Furthermore, base-deleted mutation to the Ebox almost completely suppressed the activity of the deltaE2F fragment (Figure 2c , À196/À122/mut), suggesting the role of MYCN in Bmi1 transcription. MYCN-dependent Bmi1 induction was observed not only in NB cell experiments but also in in vivo experiments. The Bmi1 mRNA level was higher in NBs occurring in tyrosine hydroxylase promoter-induced MYCN transgenic mice than in ganglions with hyperplasia and normal ganglion (S Kishida and K Kadomatsu, personal communication). Accordingly, these results suggest the important role of MYCN in Bmi1 transcription in NB and further studies will be required to address the exact mechanism of Bmi1 transcriptional regulation by E2F and/or MYCN. Supplementary Table S1 . The results are representative of at least three independent experiments. Arrows indicate alternative splicing products of KIF1Bb (Munirajan et al., 2008) . (B: KIF1Bb and C: TSLC1) SK-N-BE cells were infected with FLAG-Bmi1-expressing lentivirus and subjected to quantitative ChIP assay as described in the 'Materials and methods' section. Immunoprecipitation was performed by anti-FLAG (M2) antibody and control mouse IgG. The primers for qPCR analysis were designed using the Primer3 program (Applied Biosystems, Foster City, CA, USA) and locations are indicated in the diagrams. The primer sequences are shown in Supplementary Table S2 . The results are presented as fold enrichment and are representative of at least three independent experiments. Error bars represent the s.d. obtained with triplicate samples. Statistical significance was determined by the Mann-Whitney test.
Furthermore, the epigenetic regulation of Bmi1 transcription will be an interesting subject of NB research as we observed considerable effects of Bmi1 on other PRC complex proteins.
Taken together, we found an intriguing MYCN/ Bmi1/tumor-suppressor pathway in NB cells. This pathway might have a remarkable impact on NB tumorigenesis and is considered a target for the development of molecular targeted therapy for therapyresistant NBs.
Materials and methods

Cell culture
Human NB cell lines and QG56 human lung squamous carcinoma cells were obtained from official cell banks and were cultured in RPMI1640 or Dulbecco's modied Eagle's medium (Wako, Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 50 mg/ml penicillin/streptomycin (Sigma-Aldrich, St Louis, MO, USA) in an incubator with humidified air at 37 1C with 5% CO 2 . Tet21/N cells, which are derived from the SH-EP NB cell line, express MYCN under the control of tetracycline (tetoff system) (kindly provided by Dr M Schwab; Lutz et al., 1996) . MYCN expression in Tet21/N cells was repressed by 100 ng/ml tetracycline (Sigma-Aldrich) for 48 h before each experiment.
Treatment of cell lines with glial cell line-derived neurotrophic factor, ATRA or TPA TGW cells were seeded at a density of 1 Â 10 5 cells per 6-cm diameter tissue culture dish in the presence of glial cell linederived neurotrophic factor (Invitrogen), ATRA (SigmaAldrich) or TPA (Nacalai Tesque, Kyoto, Japan) at the concentrations indicated in figure legends, and then the cells were grown for 3 days.
Cell proliferation assay NB cells were seeded in 96-well plates at a density of 10 3 cells per well in a final volume of 100 ml. The culture was maintained under 5% CO 2 and 10 ml WST-8 labeling solution (Cell counting Kit-8; DOJINDO, Kumamoto, Japan) was added, and the cells were returned to the incubator for 2 h. The absorbance of the formazan product formed was detected at 450 nm in a 96-well spectrophotometric plate reader, according to the manufacturer's protocol.
Western blot analysis
The cells were lysed in a buffer containing 5 mM EDTA, 2 mM Tris-HCl (pH 7.5), 10 mM b-glycerophosphate, 5 mg/ml aprotinin, 2 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , protease inhibitor cocktail (Nacalai Tesque) and 1% SDS. Western blot analysis was performed as previously reported (Kurata et al., 2008) . After transferring to an Immobilon-P membrane (Millipore, Bedford, MA, USA), proteins were reacted with either anti-Bmi1 mouse monoclonal (229F6; Upstate, Charlottesville, VA, USA), anti-MYCN rabbit polyclonal (C-19; Santa Cruz, Santa Cruz, CA, USA) p14 (14P02; Oncogene) mouse, p16 (16P04; Neomarkers/Labvision, Fremont, CA, USA) mouse, anti-b-actin (Sigma-Aldrich) or a monoclonal anti-tubulin (Neomarkers Labvision) antibody. Anti-Ring1b mouse monoclonal antibodies were as described in a previous report (Atsuta et al., 2001 ).
Immunohistochemistry A 4-mm thick section of formalin-fixed, paraffin-embedded tissues was stained with hematoxylin and eosin and the adjacent sections were immunostained for Bmi1 using a polyclonal anti-Bmi1 antibody (AP2513c; ABGENT, San Diego, CA, USA). The Bench-Mark XT immunostainer (Ventana Medical Systems, Tucson, AZ, USA) and 3-3 0 diaminobenzidine detection kit (Ventana Medical Systems) were used for visualization. Appropriate positive and negative control staining was also performed in parallel for each immunostaining. The tumor samples used in this study were kindly provided from various institutions and hospitals in Japan. Informed consent was obtained at each institution and hospital. All tumors were diagnosed clinically and pathologically as NBs and MYCN copy number was determined as previously described (Kurata et al., 2008) .
Semi-quantitative RT-PCR
The methods of semi-quantitative RT-PCR analysis were previously described (Kurata et al., 2008) . Total cellular RNA to prepare RT-PCR templates was extracted from NB cell lines using Isogen (Nippon Gene K K, Tokyo, Japan), and cDNA was synthesized from 1 mg total RNA templates according to the manufacturer's protocol (RiverTra-Ace-a RT-PCR kit; TOYOBO, Osaka, Japan). Primer sequences are described in Supplementary Table S1 .
qPCR analysis for ChIP assay qPCR analysis was performed using the ABI PRISM 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions using SYBR Premix Dimer Eraser (Takara Bio, Ohtsu, Shiga, Japan). The primers for qPCR were designed and synthesized to produce 50-150 bp products. The primer sequence is listed in Supplementary Table S2 . Each sample was amplified in triplicate. In Figure 3 , the primer set was designed in E-box upstream of Bmi1 (Bmi1 promoter 1). In Figures 3, 6b , primer sets were designed in KIF1Bb (KIF1B promoter 1, 2, 3) and TSLC1 (TSLC1 promoters 1, 2, 3).
Lentiviral infection
The packaging cell line HEK 293T (4 Â 10 6 ) was plated and transfected the next day, when 1.5 mg of the transducing vectors containing the gene or shRNA, and 2.0 mg of the packaging vectors (Sigma-Aldrich) were cotransfected by the Fugene6 transfection reagent (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's protocol. The medium was changed the next day and cells were cultured for another 24 h. Conditioned medium was then collected and cleared of debris by filtering through a 0.45-mm filter (Millipore). Thereafter, 1 Â 10 5 NB cells were seeded in each well of a 6-well plate, and transduced by lentiviral-conditioned media. Transduced cells were analyzed by western blotting and RT-PCR.
Overexpression and knockdown of Bmi1
For the overexpression of Bmi1, FLAG-tagged mBmi1 plasmid was subcloned into lentivirus vector pHR-SIN-DL1. Cells were cultured in RPMI1640 and pooled. The pLKO.1-puromycin-based lentiviral vectors containing five sequence-verified shRNAs targeting human Bmi1 (RefSeq NM_005180) were obtained from the MISSION TRC-Hs 1.0 (Human) shRNA library (Sigma-Aldrich). Virus production, infection and selection were performed according to the manufacturer's protocol. At 1 week post infection, cells were harvested and knockdown efficiency was assessed by western blotting. We checked Bmi1 knockdown by the five lentivirus-produced shRNAs and used two for experiments.
Luciferase reporter assay
The À1070/ þ 53, À196/ þ 53, À196/À122, À196/À122/mut (E-box sequence CACGTG changed to CA-G-G), À1070/ þ 53 5 0 -upstream fragments were subcloned into luciferase reporter plasmid pGL4.17 (luc2/Neo) Luciferase Reporter Vector (Promega, Madison, WI, USA).
Tet21/N and SK-N-DZ cells were seeded in a 12-well plate 24 h before transfection at a concentration of 5 Â 10 4 cells per well. Cells were cotransfected with Renilla luciferase reporter plasmid (pRL-TK, 10 ng) and luciferase reporter plasmid with the 5 0 -upstream region of the Bmi1 gene. The total amount of plasmid DNA per transfection was kept constant (510 ng) with pBlueScript KS þ by Lipofectamine 2000 (Invitrogen). At 48 h after transfection, cells were lysed and their luciferase activities were measured by the Dual-Luciferase reporter system (Promega). The rey luminescence signal was normalized on the basis of the Renilla luminescence signal.
ChIP assay
ChIP assay was performed as described previously (Orlando et al., 1997 , Fujimura et al., 2006 . Cross-linked chromatin prepared from the indicated cells was precipitated with normal mouse IgG (eBioscience, San Diego, CA, USA), monoclonal anti-MYCN antibody (NCMII100; Calbiochem, San Diego, CA, USA) or anti-Flag antibody (M2; Sigma-Aldrich). 'Input' DNA was isolated from the initial lysates of genomic DNA. Species-matched immunoglobulin-immunoprecipitated DNA (IgG), derived from the same volume of the chromatin fraction used for specific antibody immunoprecipitation, was subjected to PCR. Primers used in this study are listed in Supplementary  Table S2 . Each series of experiments was conducted at least three times.
cDNA microarray experiments For gene expression profiling, in-house cDNA microarray with 13 440 spots was used. In all, 10 mg each of total RNA were labeled with the CyScribe RNA labeling kit in accordance with the manufacturer's manual (GE healthcare, Little Chalfont, Buckinghamshire, UK), followed by probe purification using the Qiagen MinElute PCR purification kit (Qiagen, Valencia, CA, USA). We used a mixture of RNAs isolated from eight human adult cancer cell lines as a common reference. RNAs from Bmi1-infected SK-N-BE and mock-infected SK-N-BE cells were labeled with Cy3 dye and a reference RNA mixture was labeled with Cy5 dye, mixed, and used as probes together with yeast tRNA and polyA for suppression. Subsequent hybridization and washing were conducted as described previously (Ohira et al., 2005) . Hybridized microarrays were scanned using the Agilent G2505A confocal laser scanner (Agilent technology, Santa Clara, CA, USA), and fluorescent intensities were quantified using the GenePix Pro microarray analysis software (Axon Instrument, Foster City, CA, USA). The resulting relative expression values for the gene spots were compared between Bmi1-infected and mock-infected SK-N-BE cells
